目的 探讨苏黄止咳胶囊联合复方甲氧那明胶囊治疗慢性阻塞性肺疾病稳定期的临床疗效。方法 选取2017年4月-2018年6月大化集团有限责任公司医院收治的慢性阻塞性肺疾病稳定期患者92例作为研究对象，全部患者按照随机数字表法分为治疗组和对照组，每组各46例。对照组口服复方甲氧那明胶囊，2粒/次，3次/d。治疗组在对照组治疗的基础上口服苏黄止咳胶囊，3粒/次，3次/d。两组患者连续治疗3个月。观察两组的临床疗效，比较两组的肺功能指标和炎症因子。结果 治疗后，对照组和治疗组的总有效率分别为78.26%、93.48%，两组比较差异有统计学意义（P<0.05）。治疗后，两组的第一秒用力呼气容积（FEV1）、第一秒用力呼气容积/最大肺活量（FEV1/FVC）、最大通气量（MVV）、残气量/肺总量（RV/TLC）均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组的肺功能指标比对照组高，两组比较差异具有统计学意义（P<0.05）。治疗后，两组的高敏C反应蛋白（hs-CRP）、白细胞介素-17（IL-17）、白细胞介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组的炎症因子水平比对照组低，两组比较差异具有统计学意义（P<0.05）。结论 苏黄止咳胶囊联合复方甲氧那明胶囊治疗慢性阻塞性肺疾病稳定期的疗效确切，能降低炎症反应，改善肺功能，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Suhuang Zhike Capsules combined with Compound Methoxynamine Capsules in treatment of stable phase of chronic obstructive pulmonary disease.Methods Patients (92 cases) with chronic obstructive pulmonary disease in stable phase in Hospital of Dahua Group Co., Ltd. from April 2017 to June 2018 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Compound Methoxynamine Capsules, 2 grains/time, three times daily. Patients in the treatment group were po administered with Suhuang Zhike Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and lung function indexes and inflammatory factors levels in two groups were compared.Results After treatment, the clinical efficacies in the control and treatment groups were 78.26% and 93.48%, respectively, and there was difference between two groups (P<0.05). After treatment, FEV1, FEV1/FVC, MVV, and RV/TLC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the lung function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of hs-CRP, IL-17, IL-8, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the inflammatory factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05).Conclusion Suhuang Zhike Capsules combined with Compound Methoxynamine Capsules has clinical curative effect in treatment of stable phase of chronic obstructive pulmonary disease, can reduce inflammation reaction, and improve lung function, which has a certain clinical application value.